The moral challenge of our era is not whether intelligence should expand, but whether human beings retain agency, sovereignty, and the capacity for flourishing within that expansion.
Thomas Oxley
Verified account This account is verified. Learn more@tomoxl
Founder & CEO Synchron @synchroninc
184 Following 11K Followers 353 Posts
Latest posts 5
"We're all going to die, but let's accelerate anyway." That's the strange logic behind (self-serving) AGI alarmism. Merge-ASAP cheerleading, like this, is the same. Both obscure the moral goal in BCI, which deserves deeper attention: to serve and protect human agency.
While your laptop is closed, AI is already getting better at your job, says tech entrepreneur D. Scott Phoenix (@fuelfive).
Here’s why he says that rather than competing with AI, humans need to merge with it instead: t.ted.com/m2xQG0PView quoted post on X
www.reuters.com Convicted former Harvard scientist rebuilds brain computer lab in China An American scientist convicted of lying to U.S. authorities about payments from China while he was at Harvard University has rebuilt his research lab in Shenzhen to pursue technology the Chinese... So true
Prediction: When Iranians overthrow their brain-rotted religious dictator, become a liberal democracy, and rejoin the global economy, they’ll become one of the biggest economic powers in the world. Iranians are some of the smartest, hardest-working, and most entrepreneurial people I’ve ever met.View quoted post on X
💯. Need dynamic FDA leadership to break the shackles. There’s plenty of room to safely pull back, and unleash USA’s potential.
Specific recommendations for FDA and regulators so we do not lose to China.View quoted post on X
•First-in-human (FIH) trials are the earliest and most important value-inflection point in biotech, determining whether early companies can raise the capital needed to advance development.
•FDA’s pre-IND and IND processes create significant uncertainty for companies. Pre-IND recommendations are non-binding, companies typically receive only a single meeting, and guidance can be inconsistent. As a result, sponsors often over-engineer studies to avoid the risk of clinical holds after IND submission.
•The U.S. is steadily losing FIH trials overseas. More U.S. biotech are choosing to conduct FIH studies in China and Australia due to faster, more predictable, and lower-cost pathways abroad.
•Piloting a mechanism like Australia’s clinical trial notification (CTN) pathway would allow companies to begin FIH trials after ethics approval and FDA notification, dramatically improving speed and predictability.
•Standards would not be lowered: responsibility shifts to sponsors, while FDA retains authority to audit, intervene, and halt trials if safety concerns arise.
•Retaining FIH trials is strategic, preserving U.S. leadership in translational science, biotech investment, and national-security-critical countermeasure development.
